Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents


ANGELERGUES A., EFSTATHIOU E., GYFTAKI R., WYSOCKI P. J. , LAINEZ N., GONZALEZ I., ...More

CLINICAL GENITOURINARY CANCER, vol.16, no.4, 2018 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 16 Issue: 4
  • Publication Date: 2018
  • Doi Number: 10.1016/j.clgc.2018.02.016
  • Title of Journal : CLINICAL GENITOURINARY CANCER
  • Keywords: ART, Metastatic CRPC, Survival, Taxanes, Treatment sequence, PHASE-III TRIALS, ABIRATERONE ACETATE, OPEN-LABEL, CHEMOTHERAPY, THERAPY, MEN, ENZALUTAMIDE, SURVIVAL, EFFICACY, OUTCOMES

Abstract

Several agents have demonstrated an overall survival (OS) benefit in metastatic castration-resistant prostate cancer (mCRPC); however, optimal sequencing is unknown. Retrospective analysis of data from 574 mCRPC patients showed increasing OS with the number of therapies provided; a sequence including docetaxel, cabazitaxel (CABA), and an androgen receptor-targeted agent (ART) provided the greatest benefit. Prior administration of ART did not appear to influence CABA activity. These findings will help guide treatment decisions in daily practice.